Wire · opportunities
Trial paper is retracted as FDA keeps scrutiny on controversial vasculitis drug
◆ Sectors
Digital Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 9 July 2026 · Fusion42 review
A pivotal vasculitis drug trial (avacopan/Tavneos) has been retracted by NEJM after FDA found evidence of data manipulation; the EMA is revoking its marketing authorisation, creating major regulatory uncertainty for the drug's continued approval.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
Founders in clinical-stage biotech must understand that data integrity breaches trigger cascading regulatory failures across territories; trial retractions and approvals revocation signal tightened FDA/EMA scrutiny on trial conduct and patient safety claims.
◆ Coverage
1 source · 9 Jul 2026
◆ Related on Wire
◆ Topics
Digital Healthdata-integritydrug-approvalfda-scrutinyvasculitisclinical-trialsregulatory-risk